• Explore /
  • Poster
  • / A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma.

A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma.

Abstract Poster

Authors

null

Neha Mehta-Shah

Memorial Sloan Kettering Cancer Center, New York, NY

Neha Mehta-Shah , Matthew Alexander Lunning , Adam M. Boruchov , Jia Ruan , Sumithra Nair , Peggy Lynch , Regina Byrne , Alison J. Moskowitz , Matthew J. Matasar , John F. Gerecitano , Paul A. Hamlin , John Leonard , Craig H. Moskowitz , Patricia L. Myskowski , Christiane Querfeld , Patrick Nolan , Maria Lia Palomba , David J. Straus , Andrew David Zelenetz , Steven M. Horwitz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Lymphoma

Clinical Trial Registration Number

NCT01755975

Citation

J Clin Oncol 33, 2015 (suppl; abstr 8521)

DOI

10.1200/jco.2015.33.15_suppl.8521

Abstract #

8521

Poster Bd #

338

Abstract Disclosures

Similar Posters

First Author: Matthew Alexander Lunning

First Author: Nathan Hale Fowler

First Author: James D. Hilger

First Author: James R. Berenson